Page 264 - 2021_06-Haematologica-web

1766
Letters to the Editor
Stine U. Mikkelsen,1,2 Setareh Safavi,3
Konstantinos Dimopoulos,4 Colm J. O’Rourke,2
Mette K. Andersen,3 Mette S. Holm,5 Claus W. Marcher,6 Jesper B. Andersen,2 Jakob W. Hansen1,2,7#
and Kirsten Grønbæk1,2,7#
1Department of Hematology, Rigshospitalet, Copenhagen; 2Biotech Research and Innovation Center (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen; 3Department of Clinical Genetics, Rigshospitalet, Copenhagen; 4Department of Clinical Biochemistry, Rigshospitalet, Copenhagen; 5Department of Hematology, Aarhus University Hospital, Aarhus; 6Department of Hematology, Odense University Hospital, Odense and 7DanStem, University of Copenhagen, Copenhagen, Denmark
#JWH and KG contributed equally as co-senior authors. Correspondence:
KIRSTEN GROENBAEK - kirsten.groenbaek@regionh.dk doi:10.3324/haematol.2020.263319
Received: June 13, 2020.
Accepted: November 2, 2020. Pre-published: November 12, 2020. Disclosures: no conflicts of interest to disclose.
Contributions: SUM wrote the manuscript, collected patient data, performed laboratory analysis (SNP-A), performed analysis of SNP-A data, performed statistical analyses, prepared the tables and figures and applied for funding; SS performed analysis of SNP-A data; KD performed statistical analyses and prepared the figures. CJR performed laboratory analysis (SNP-A); MKA performed genetic and chromosomal analyses; MSH recruited patients; CWM recruited patients. JBA supervised the study; JWH designed the study, managed the biobank, extracted the DNA, collected patient data, performed targeted next generation sequencing, supervised the study and applied for funding; KG designed the study, managed the biobank, supervised the study and applied for funding. All authors contributed to the critical reviewing and editing of the manuscript.
Acknowledgments: the authors would like to thank the Danish Cancer Society (grant no. R204-A12363), the administrators of Rigshospitalet’s Research Funds and Greater Copenhagen Health Science Partners who provided grants that covered the salary for SUM. The authors would also like to thank Aase og Ejnar Danielsens Fond and the administrators of Frk. Amalie Jørgensens Mindelegat for research grants to SUM and JWH, respectively.
Funding: the project is part of the Danish Research Center for Precision Medicine in Blood Cancers funded by the Danish Cancer Society (grant no. R223-A13071) and Greater Copenhagen Health Science Partners. The Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) is supported by a Novo Nordisk Foundation grant (grant no. NNF17CC0027852).
References
1. Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126(21):2355-2361.
2.Malcovati L, Gallì A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017; 129(25):3371-3378.
3. Kanagal-Shamanna R, Hodge JC, Tucker T, et al. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: an evidence based review of clinical util- ity from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genet. 2018;228-229:197-217.
4. Xu X, Bryke C, Sukhanova M, et al. Assessing copy number abnor- malities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: an evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet. 2018;228- 229:218-235.
5.Ronaghy A, Yang RK, Khoury JD, Kanagal-Shamanna R. Clinical applications of chromosomal microarray testing in myeloid malig- nancies. Curr Hematol Malig Rep. 2020;15(3):194-202.
6. Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549-1556.
7. Tiu RV, Gondek LP, O’Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117(17):4552-4560.
8. Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastie syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free sur- vival. Blood. 2008;112(8):3412-3424.
9. Evans AG, Ahmad A, Burack WR, Iqbal MA. Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syn- dromes and cytopenias of undetermined significance. Mod Pathol. 2016;29(10):1183-1199.
10.Cargo CA, Rowbotham N, Evans PA, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease pro- gression. Blood. 2015;126(21):2362-2365.
11. Xiao X, He X, Li Q, et al. Single-nucleotide polymorphism array tech- nique generating valuable risk-stratification information for patients with myelodysplastic syndromes. Front Oncol. 2020;10:962.
12. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44(6):642-650.
13. Mohamedali AM, Gäken J, Ahmed M, et al. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia. 2015;29(9):1928-1938.
14. Thiel A, Beier M, Ingenhag D, et al. Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recur- rent and individual genomic copy number alterations with prognos- tic relevance. Leukemia. 2011;25(3):387-399.
15. O’Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of het- erozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731-2739.
haematologica | 2021; 106(6)